Search   
MSDS  : 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5, 6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-, (4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alp ha))-
CAS  : 79-57-2
SYNONYMS  : * Adamycin * Antibiotic TM 25 * Berkmycen * Biostat * Biostat PA * Geomycin * Dabicycline * Fanterrin * Geomycin (Streptomyces vimosus) * Geotilin * 5-Hydroxytetracycline * LA 200 * Lenocycline * Liquamycin LA 200 * Macocyn * Mycoshield TMQTHC 20 * NCI-C56473 * Oksisyklin * OTC * OTC (antibiotic) * Oxitetracyclin * Oxymycin * Oxymykoin * Oxypam * Oxyterracin * Oxyterracine * Oxyterracyne * Oxytetracycline * Oxytetracycline amphoteric * Proteroxyna * Riomitsin * Ryomycin * Solkaciclina * Stevacin * Tarosin * Terrafungine * Terramycin Q50 * Terramitsin * Terramycin * Tetracycline, 5-hydroxy- * Tetran * Ursocyclin * Ursocycline * Vendarcin
*** CHEMICAL IDENTIFICATION ***

RTECS NUMBER : QI7875000
CHEMICAL NAME : 2-Naphthacenecarboxamide,
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,
6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,
(4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alp
ha))-
CAS REGISTRY NUMBER : 79-57-2
BEILSTEIN REFERENCE NO. : 2714587
REFERENCE : 4-14-00-02633 (Beilstein Handbook Reference)
LAST UPDATED : 199707
DATA ITEMS CITED : 28
MOLECULAR FORMULA : C22-H24-N2-O9
MOLECULAR WEIGHT : 460.48
WISWESSER LINE NOTATION : L E6 C666 BV FV CU GUTTT&J DQ EQ GVZ HQ IN1&1 KQ MQ
M1 RQ
COMPOUND DESCRIPTOR : Agricultural Chemical
Drug
Mutagen
Reproductive Effector
Human
SYNONYMS/TRADE NAMES :
* Adamycin
* Antibiotic TM 25
* Berkmycen
* Biostat
* Biostat PA
* Geomycin
* Dabicycline
* Fanterrin
* Geomycin (Streptomyces vimosus)
* Geotilin
* 5-Hydroxytetracycline
* LA 200
* Lenocycline
* Liquamycin LA 200
* Macocyn
* Mycoshield TMQTHC 20
* NCI-C56473
* Oksisyklin
* OTC
* OTC (antibiotic)
* Oxitetracyclin
* Oxymycin
* Oxymykoin
* Oxypam
* Oxyterracin
* Oxyterracine
* Oxyterracyne
* Oxytetracycline
* Oxytetracycline amphoteric
* Proteroxyna
* Riomitsin
* Ryomycin
* Solkaciclina
* Stevacin
* Tarosin
* Terrafungine
* Terramycin Q50
* Terramitsin
* Terramycin
* Tetracycline, 5-hydroxy-
* Tetran
* Ursocyclin
* Ursocycline
* Vendarcin

*** HEALTH HAZARD DATA ***

** ACUTE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Human - man
DOSE/DURATION : 114 mg/kg/4D
TOXIC EFFECTS :
Blood - hemorrhage
Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N.
Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year:
231,734,1975

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Parenteral
SPECIES OBSERVED : Human - infant
DOSE/DURATION : 136 mg/kg
TOXIC EFFECTS :
Musculoskeletal - changes in teeth and supporting structures
REFERENCE :
LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823-
Volume(issue)/page/year: 1,827,1962

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 4800 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
85ERAY "Antibiotics: Origin, Nature, and Properties," Korzyoski, T., et al.,
eds., Washington, DC, American Soc. for Microbiology, 1978
Volume(issue)/page/year: 1,501,1978

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 260 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
85ERAY "Antibiotics: Origin, Nature, and Properties," Korzyoski, T., et al.,
eds., Washington, DC, American Soc. for Microbiology, 1978
Volume(issue)/page/year: 1,501,1978

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 2240 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 5,1,1955

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 5706 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher
information, see AMBIEH. Volume(issue)/page/year: 20,793,1975

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 700 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
85GDA2 "CRC Handbook of Antibiotic Compounds," Vols.1- , Berdy, J., Boca
Raton, FL, CRC Press, 1980- Volume(issue)/page/year: 3,44,1980

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 140 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 5,1,1955

TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : 220 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
Behavioral - food intake (animal)
Lungs, Thorax, or Respiration - other changes
REFERENCE :
ANTCAO Antibiotics and Chemotherapy (Washington, DC). (Washington, DC)
V.1-12, 1951-62. For publisher information, see CLMEA3.
Volume(issue)/page/year: 3,1015,1953

TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - guinea pig
DOSE/DURATION : 2250 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher
information, see AMBIEH. Volume(issue)/page/year: 20,793,1975

** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 6 gm/kg/30D-I
TOXIC EFFECTS :
Gastrointestinal - other changes
Kidney, Ureter, Bladder - other changes in urine composition
Immunological Including Allergic - decreased immune response
REFERENCE :
ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher
information, see AMBIEH. Volume(issue)/page/year: 20,793,1975

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 160 mg/kg/12D-I
TOXIC EFFECTS :
Immunological Including Allergic - decrease in cellular immune response
Immunological Including Allergic - hypersensitivity delayed
REFERENCE :
TOXID9 Toxicologist. (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway,
Akron, OH 44311) V.1- 1981- Volume(issue)/page/year: 6,69,1986

** REPRODUCTIVE DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Unreported
SPECIES OBSERVED : Human - woman
DOSE : 420 mg/kg
SEX/DURATION : female 1-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - other postnatal measures or effects
REFERENCE :
JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N.
Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year:
188,178,1964

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 1 gm/kg
SEX/DURATION : female 6-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured
before birth)
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
e.g., stunted fetus)
Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
OSDIAF Osaka Shiritsu Daigaku Igaku Zasshi. Journal of the Osaka City
Medical Center. (Osaka, Japan) V.4-23, 1955-74. For publisher
information, see OIGZDE. Volume(issue)/page/year: 14,107,1965

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 1 gm/kg
SEX/DURATION : female 6-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear
Reproductive - Specific Developmental Abnormalities - urogenital system
REFERENCE :
OSDIAF Osaka Shiritsu Daigaku Igaku Zasshi. Journal of the Osaka City
Medical Center. (Osaka, Japan) V.4-23, 1955-74. For publisher
information, see OIGZDE. Volume(issue)/page/year: 14,107,1965

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE : 800 mg/kg
SEX/DURATION : female 10-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including
somatic cell genetic material)
Reproductive - Effects on Embryo or Fetus - other effects to embryo
REFERENCE :
AEMBAP Advances in Experimental Medicine and Biology. (Plenum Pub. Corp.,
233 Spring St., New York, NY 10013) V.1- 1967- Volume(issue)/page/year:
27,291,1972

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Parenteral
SPECIES OBSERVED : Rodent - mouse
DOSE : 800 mg/kg
SEX/DURATION : female 12-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
REFERENCE :
VHAGAS Verhandlungen der Anatomischen Gesellschaft. (VEB Gustav Fischer
Verlag, Postfach 176, Jena, DDR-6900, Ger. Dem. Rep.) V.1- 1887-
Volume(issue)/page/year: 67,551,1973

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Mammal - dog
DOSE : 643 mg/kg
SEX/DURATION : female 18-48 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or
resorbed implants per total number of implants)
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
Reproductive - Specific Developmental Abnormalities - body wall
REFERENCE :
THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris,
France) V.1- 1946- Volume(issue)/page/year: 23,1247,1968

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Mammal - dog
DOSE : 643 mg/kg
SEX/DURATION : female 18-48 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - gastrointestinal
system
Reproductive - Specific Developmental Abnormalities - urogenital system
Reproductive - Specific Developmental Abnormalities - other developmental
abnormalities
REFERENCE :
THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris,
France) V.1- 1946- Volume(issue)/page/year: 23,1247,1968

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Rodent - rabbit
DOSE : 789 mg/kg
SEX/DURATION : female 10-28 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or
resorbed implants per total number of implants)
REFERENCE :
THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris,
France) V.1- 1946- Volume(issue)/page/year: 23,1247,1968

** MUTATION DATA **

TYPE OF TEST : Sperm Morphology
ROUTE OF EXPOSURE : Unreported
TEST SYSTEM : Rodent - rat
DOSE/DURATION : 80 mg/kg/8D
REFERENCE :
JOURAA Journal of Urology. (Williams & Wilkins Co., 428 E. Preston St.,
Baltimore, MD 21202) V.1- 1917- Volume(issue)/page/year: 112,348,1974

*** REVIEWS ***

TOXICOLOGY REVIEW
AJMEAZ American Journal of Medicine. (Technical Pub., 875 Third Ave., New
York, NY 10022) V.1- 1946- Volume(issue)/page/year: 38,409,1965

TOXICOLOGY REVIEW
CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate
Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year:
2,159,1973

TOXICOLOGY REVIEW
ADTEAS Advances in Teratology. (New York, NY) V.1-5, 1966-72.
Discontinued. Volume(issue)/page/year: 2,239,1967

*** U.S. STANDARDS AND REGULATIONS ***

EPA FIFRA 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION
FEREAC Federal Register. (U.S. Government Printing Office, Supt. of
Documents, Washington, DC 20402) V.1- 1936- Volume(issue)/page/year:
54,7740,1989

*** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA ***

NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA :
NOHS - National Occupational Hazard Survey (1974)
NOHS Hazard Code - 84638
No. of Facilities: 537 (estimated)
No. of Industries: 5
No. of Occupations: 14
No. of Employees: 3836 (estimated)

NOES - National Occupational Exposure Survey (1983)
NOES Hazard Code - 84638
No. of Facilities: 478 (estimated)
No. of Industries: 3
No. of Occupations: 7
No. of Employees: 10418 (estimated)
No. of Female Employees: 7548 (estimated)

*** STATUS IN U.S. ***

EPA TSCA Section 8(b) CHEMICAL INVENTORY


*** END OF RECORD ***
Search More   
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
NAMECAS
Myxovalargin A 82658-75-1
Myxovalargin B 85568-63-4
4-Morpholinepropanamine,N-(5-chloro-2-nitrobenzo(b)thien-3-yl)- 149338-22-7
Myxovalargin C 85568-64-5
Myxovalargin D 85568-65-6
Naematolin 11054-16-3
Nagase (bacillus subtilis) 11054-16-3
Najatoxin 11054-16-3
Named reagents and solutions, cpd 39374-34-0
4a-epi-Nanaomycin B 72691-97-5
Nandina domestica Thunb., stem extractSUBSTANCE DEFINITION :Plant containing berberine-type alkaloidsREFERENCE :YKKZAJ Yakugaku Zasshi. Journal of Pharmacy. (Nippon Yakugakkai, 2-12-15Shibuya, Shibuya-ku, Tokyo 150, Japan) No.1- 1881-Volume(issue)/page/year: 82,726,1962 72691-97-5
Naphth(2,3-a)aceanthrylene 84030-79-5
Naphthacene 92-24-0
4-Morpholinepropanamine,N-(3-chlorophenyl)-2,6-dimethyl-N-4-pyridinyl-,mono(2-hydroxybenzoate) 59235-63-1
2-Naphthacenecarboxamide,N-((4-(amidinoamidino)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-di oxo- 16545-11-2
2-Naphthacenecarboxamide,N-((4-(amidinoamidino)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-diox o-, dihydrochloride 13040-98-7
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo- 10118-90-8
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5a-alpha,12a-alpha))-,disulfate (1:2) (salt) 10118-90-8
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-,monohydrochloride 13614-98-7
2-Naphthacenecarboxamide,7-bromo-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10- 12,12a-pentahydroxy-6-methyl-1,11-dioxo- 4572-56-9
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,12a-decahydro-1,11-dioxo-N-(hydroxymethyl)-6-methyl-3,6,10,12,12a-pentahydroxy- 1181-54-0
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-1,11-dioxo- 127-33-3
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-1,11-dioxo-,monohydrochloride 64-73-3
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo- 57-62-5
4-Morpholinepropanamine,N-(3-chlorophenyl)-beta-methyl-N-4-pyridinyl-, (Z)-2-butenedioate (1:2) 21957-74-4
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 64-72-2
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo- 2013-58-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alpha))- 79-57-2
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-,calcium salt (1:1),(4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alpha))- 7179-50-2
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12, 12a-hexahydroxy-6-methyl-1,11-dioxo-,disodium deriv., dihydrate 6153-65-7
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-2,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,monohydrochloride, mixed with potassium nitrite 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-, compd.with sodium nitrite (1:3) 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-, sodiumsalt 69766-62-7
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12, 12a-hexahydroxy-6-methyl-1,11-dioxo-,sulfate 64038-91-1
4-Morpholinepropanamine,N-(3-chlorophenyl)-N-4-pyridinyl-,bis(2-hydroxybenzoate) 21928-15-4
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-N-((4-(2-hydroxyethyl)-1-piperazinyl)methyl)-6-methyl-1,11-di oxo- 1110-80-1
2-Naphthacenecarboxamide,4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,11,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dioxo- 564-25-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo- 60-54-8
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 10592-13-9
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 64-75-5
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)- 751-97-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-, mononitrate (salt) 20685-78-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5a-alpha,6-beta,12a-alpha))-,compd. with 4-hydroxy-3-methoxybenzenesulfonate (1:1) 20228-26-6
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo- 914-00-1
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a- pentahydroxy-6-methylene-1,11-dioxo-,monohydrochloride 3963-95-9
4-Morpholinepropanamine,N-(3-chlorophenyl)-N-4-pyridinyl-beta,2,6-trimethyl-,mono(2-hydroxybenzoate) 23410-76-6
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-9-(morpholinomethyl)-1,11-dioxo- 67238-91-9
2-Naphthacenecarboxamide,N,N'-(ethylenebis((methylimino)methylene))bis(4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-di oxo- 17910-68-8
2-Naphthacenecarboxamide,1,4,4a,5,12,12a-hexahydro-4-(dimethylamino)-1,12-dioxo-6-methyl- 3,10,11,12a-tetrahydroxy-,(4S-(4-alpha,4a-alpha,12a-alpha))- 1665-56-1

Free MSDS Search ( Providing 250,000+ Material Properties )
Chemcas.com| Ads link:todaystock.net